Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $2.99 up 1.70% from its previous closing price of $2.94. In other words, the price has increased by $1.70 from its previous closing price. On the day, 1.12 million shares were traded. ZNTL stock price reached its highest trading level at $3.1 during the session, while it also had its lowest trading level at $2.92.
Ratios:
For a deeper understanding of Zentalis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.59. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 04 ’24 when Vultaggio Vincent sold 1,603 shares for $3.18 per share. The transaction valued at 5,098 led to the insider holds 33,855 shares of the business.
Gallagher Cam sold 9,597 shares of ZNTL for $114,972 on May 31 ’24. The President, Interim CFO now owns 633,680 shares after completing the transaction at $11.98 per share. On May 09 ’24, another insider, HAUSMAN DIANA, who serves as the Chief Medical Officer of the company, sold 3,356 shares for $12.62 each. As a result, the insider received 42,353 and left with 373,876 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 212612928 and an Enterprise Value of -169745184. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.24 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at -4.185 whereas that against EBITDA is 0.774.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $21.34, while it has fallen to a 52-week low of $2.83. The 50-Day Moving Average of the stock is -11.11%, while the 200-Day Moving Average is calculated to be -67.67%.
Shares Statistics:
For the past three months, ZNTL has traded an average of 1.77M shares per day and 1171260 over the past ten days. A total of 70.77M shares are outstanding, with a floating share count of 61.39M. Insiders hold about 13.67% of the company’s shares, while institutions hold 100.06% stake in the company. Shares short for ZNTL as of 1727654400 were 8636183 with a Short Ratio of 4.89, compared to 1724976000 on 12281137. Therefore, it implies a Short% of Shares Outstanding of 8636183 and a Short% of Float of 24.51.
